The uplisting is one area in which I feel pretty good about the timeline. The vast majority of it seems to be meeting the listing requirements and the NASDAQ folks doing their due diligence. If we meet the requirements, which all the key folks have said we do, then I anticipate it falling in line.

I think the lingering doubt about timelines that many of us feel is completely valid but also a result of the constantly changing landscape. I remember one of the conference calls we had after the EIND's were in full swing and Dr. J said that they went to the FDA on something like 4 previous occasions asking for emergency use. The first time was after the first few patients at Montefiore and then as great results kept occurring they kept asking.

Hell, you can't blame them for asking as well as for thinking it had a chance of working. That's why we're all here, after all. Because we see it already. The FDA either doesn't see it (yet) or they see it but aren't about to get burned by a small company when all eyes across the world are on them to fix this problem. (or of course there is big pharma influence keeping it down) But the point is our leaders have been gameplanning for a timeline to approval that has shifted constantly as new data and new hope arrives on a near constant basis. If X happens you do Y and Z. If X gets delayed you scrap Y and maybe Z, and then move over to U and V. A week later there's new results and you're back on the Y and Z train.

All of the ancillary but important factors have to change with the end goal. The deal you're going to get from an institutional investor or the amount of product you are going to contractually sign on to receive is going to swing wildly as things like results, approval, and licensing/partnerships advance. They are all tied together.

I really felt like NP's goal has been (pre-covid) to get as many balls in the air that he can. Balls that are just far enough along to prove what Leronlimab can do, but not so far that it requires a ton of money and time to get there. The idea being that we would become more valuable both for shareholders and for a potential buyout. And as new opportunities like Covid presented themselves it went from "let's see if we can test the waters a little" to "hey guys, we may have something special here" and when you have limited resources you have to dead-end a few paths to cut your new one.

This theory can help explain why things popped up and then seemed to disappear a lot over the last couple months. Like MS, for instance. Or the initial attempts to get things rolling in the UK. Licensing. Institutional investors. We're all so anxious to see Leronlimab get its fair shake, to help the world, to make us money, that it's hard to not get frustrated with every delay or shift in strategy.

But you make the best decisions you can as the information in front of you allows. You plan and scheme, hoping the spark you keep throwing out catches and a fire erupts. Every so often it looks like you're good but the wind changes direction so you shift and get back after it. And sure, they are all trying to figure this thing out as it goes along to some extent, learning as they go, and you could argue someone with a ton of experience could have accelerated the timeline a little. But I trust all of them and have no doubt that it's going to happen. Even if they have to shift the goalposts a few more times before it does.